$WOLV Cyber Crime ~ There's an App for That™ Ladies &

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
$WOLV Cyber Crime ~ There's an App for That™
Ladies & Gentlemen
Cyber-crime is growing rapidly and is now crippling business and personal
identities on a daily basis. Today there are already in excess of 4 billion
mobile devices all running on Mobile Applications (software). Be they
from Apple, Google Android, BlackBerry or a host of others, they all have
an inherent flaw: none can protect or secure the device they run on from
hacking or intrusion with 100% certainty. (There are countless stories on the news web)

Security on computer equipment is now at a level of crisis; as was stated
by the US Government it is the single greatest threat to American
sovereignty - outweighing the War on Terrorism.

"How is this possible?"

The full answer is very complex as it is the same cause that has our
corporate and government computers the victims of billions of dollars in
losses from Cyber-crime and intrusion, fraud and intellectual property
theft. The short answer is that a software "App" must be watched at every
step as it internally processes data in order to keep it safe.

Thousands of companies have created technologies to watch data as it goes
"into" and "out of" the software, looking for anomalous or erroneous
activity that may have occurred. However none can watch the bit-by-bit
processing "inside" as the software is operating. No software can "watch
itself" to ensure the work it is doing is correct or authorized. There-in
lies the entire Cyber Security problem.

ENIGMAMobil™ has changed that paradigm and is creating ~ an app for that.

Within the first three pages of the easy read Investment document attached, you will
discover why the problem has never been solved before and what has now been
invented to solve this global crisis now.

What you are looking at here is a very rare world monopoly in one of the
largest revenue markets: Technology.

"Why doesn't someone else come up with the solution in the meantime?"

Quick Answer: The problem has been systemic for 45 years with no solution
and with the cyber crisis worsening every day, no one sees a short term
resolve. In fact, an $18 Billion contract was just pulled from one of the
largest security developers, CDC (for the Federal Government), by Congress
after 3 years into an attempt to solve the problem, citing the company had
made no acceptable progress toward a solution.

Even though the solution technology is fully patent protected (20yr), we do
not rest alone on that. ENIGMAMobil™ will be in the market 10 months
after this financing. Should another company attempt to create similar
software, they would not only be up against the patent, but the
game-changing language "Vulcan™( the patent name )", as discussed here-in, took a further 10
years of focused development to create. This "Vulcan™" language is
available exclusively to ENIGMAMobil™.

First to market solving a $2 Trillion dollar crisis has a clear "rite
of passage" for success. Patent aside again, the problem will have been
solved by ENIGMA, a new standard will have been set for security and the
spoils go to the victor.

To further enhance the investment the company has been structured with a
clear exit strategy in mind which is clearly defined inside the document.

This is a one-time opportunity for investment with no watering down to
follow. This is not so much about finding investors to risk - it is about
investors that are clear and informed on the problem and want to realize a
large gain for their knowledge of the magnitude of the problem.

I intend to have this financing closed in the short term. The market is
demanding a solution - the technology is ready.

Warm wishes,

David Chalk

(Dr.) David Chalk, d.Tech.
David Chalk Inc.
david@davidchalkinc.com

http://enigmamobile.com/

"You never change things by fighting the existing reality.
To change something, build a new model that makes the existing model
obsolete."
-- Richard Buckminster Fuller
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

You Call The Play Inc. (YCTP) Leads with Integrity in Betting

Updated Category News Views 154

Understanding You Call The Play Inc. (YCTP)'s Initiative In an important move for the sports betting landscape, You Call The Play Inc. (YCTP) has recently unveiled a national licensing plan and a groundbreaking measure called the Safe Bet Overlay™. This initiative is designed to foster trust and transparency within an industry that continues to grow rapidly across the...

Continue Reading
Cash for Houses Pro Earns Stellar Reputation with 5-Star Reviews

Updated Category News Views 167

Cash for Houses Pro Achieves 5-Star Reviews Cash for Houses Pro is celebrating their recent success in receiving numerous 5-star reviews on Google for their service known as 'Sell Your House Fast In Tampa FL For Cash'. This recognition reflects the team's dedication to providing homeowners with a seamless and stress-free home selling experience. About Cash for Houses Pro...

Continue Reading
Pfizer's Potential Transformation Following Starboard Investment

Updated Category News Views 77

Pfizer's Revised Price Target and Market Standing Recently, CFRA, a prominent financial research firm, elevated its price target for Pfizer Inc. (NYSE:PFE) from $30.00 to $31.00 per share. This adjustment comes while maintaining a 'Hold' rating on the stock, suggesting a careful observation of its market performance. The current price target reflects a valuation based on...

Continue Reading
Equinox Gold's Impressive Q2 Results Spark Stock Surge Today

Updated Category News Views 103

Equinox Gold Delivers Strong Quarterly Performance Equinox Gold Corp. EQX has seen its shares rise significantly following the release of its second-quarter financial results, which exceeded market expectations. Investors reacted favorably, driving the stock up on Thursday. Financial Highlights from the Quarter In the latest quarterly report, Equinox Gold announced...

Continue Reading
Investor Insights on Alexandria Real Estate Equities' Legal Challenges

Updated Category News Views 219

Understanding the Alexandria Real Estate Equities, Inc. Lawsuit Investors have an important opportunity arising from a lawsuit against Alexandria Real Estate Equities, Inc. (NYSE: ARE). A national shareholder rights litigation firm has initiated a class action alleging the Company has violated various securities laws. This situation has caught the attention of many...

Continue Reading